Rating Change
Guggenheim reiterated its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) on August 10, 2026.
reiterateNASDAQ:CTMX
Guggenheim Reiterates Buy Rating on CytomX Therapeutics, Inc. (CTMX)
Guggenheim reiterated its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) on August 10, 2026.
At publication ·
What changed
CytomX Therapeutics, Inc. (NASDAQ:CTMX) · reiterate
- Firm
- Guggenheim
- Rating
- Buy to Buy
- Price at event
- $3.44
- Market capitalization
- $686.8M
At a glance
Key takeaways
- Guggenheim reiterated its Buy rating on CytomX Therapeutics (CTMX) on August 10, 2026, with the stock trading at $3.44 and a market capitalization of $686.8 million.
Market Context
CytomX Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.44 with a market capitalization of $686.8M.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CytomX Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CytomX Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | Guggenheim | Buy | N/A |
| May 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 23, 2026 | Piper Sandler | Overweight | N/A |
| Mar 19, 2026 | Barclays | Overweight | N/A |
| Mar 18, 2026 | Jefferies | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CTMX Stock Page
Frequently Asked Questions
What does the Buy rating mean for CTMX?
A rating of Buy from Guggenheim reflects the analyst's outlook on CytomX Therapeutics, Inc. (NASDAQ:CTMX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CTMX forecast page.
